Cantor Fitzgerald upgraded Verve Therapeutics (VERV) to Overweight from Neutral without a price target following the initial Heart-2 Phase 1 data. VERVE-102 exceeded expectations, both for safety and efficacy, the analyst tells investors in a research note. The firm says the 53% reduction in low-density lipoprotein cholesterol seen at the 0.6 mg/kg dose suggests that VERVE-102 could be best-in-class for achieving LDL-C goals in heterozygous familial hypercholesterolemia. Cantor now sees Verve shares as undervalued.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERV:
- Verve Therapeutics price target raised to $39 from $32 at Canaccord
- Verve Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
- Verve Therapeutics price target raised to $25 from $15 at H.C. Wainwright
- Buy Rating for Verve Therapeutics: Promising Safety and Efficacy of VERVE-102 in Phase 1b Heart-2 Study
- Verve announces initial data from Heart-2 Phase 1b trial of VERVE-102